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аннотация
Введение. Эффективность противоракового лечения зависит от биологических факторов опухоли. 
цель исследования – определить активность протеасом и кальпаинов и выявить их связь с содержа-
нием VEGF, HIF-1α и NF-κΒ в опухолевых, неизмененных и метастатических тканях карциномы почек 
(RCC). материал и методы. В исследование были включены 93 пациента с почечно-клеточным раком. 
Содержание транскрипционных факторов и VEGF определяли методом ИФА. Количественный состав 
протеасом исследовали методом Вестерн-блоттинг. Активность протеасомы и кальпаина определяли 
с использованием специфического флюорогенного субстрата. результаты. Выявлена инактивация 
протеолиза у пациентов с раком почки. Прогрессирование заболевания было связано со значительным 
снижением уровня клеточного протеолиза и ростом содержания транскрипционных и ростовых факторов 
в тканях первичной опухоли. Активация протеолиза была обнаружена в метастатических тканях. Вы-
воды. В результате проведенного исследования показано, что факторы транскрипции NF-κΒ, HIF-1α, 
VEGF и внутриклеточные протеолитические системы участвуют в прогрессировании рака почки.
Ключевые слова: рак почки, метастазы, NF-кВ, HIF-1α, VEGF.
IMPACT OF TRANSCRIPTION FACTORS, VEGF AND 
PROTEASES ON KIDNEY CANCER PROGRESSION
L.V. Spirina1,2, I.V. Kondakova1, E.A. usynin1, E.M. Slonimskaya1,2, 
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Abstract
Introduction. The efficacy of anticancer treatment depends on biological factors of tumor. The aim of the 
study was to determine the activity of proteasomes and calpains and to reveal their association with VEGF, 
HIF-1α and NF-κΒ expressions in normal, primary and metastatic renal cell carcinoma (RCC) tissues. 
Methods. Ninety-three patients with renal cell carcinoma were included into the study. The expression levels 
of transcription factor and VEGF were measured using ELISA kits. The levels of proteasome subunits were 
measured by Western Blotting. proteasome and calpain activities were determined using specific fluorogenic 
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substrates. Results. We revealed inactivation of proteolysis in patients with kidney cancer. disease advance 
was associated with a significant depression of cellular proteolysis and increase in transcription and growth 
factor levels in primary kidney cancer tissues. The proteolysis activation was found in metastatic tissues. 
Conclusions. our results suggest that NF-κΒ, HIF-1α and VEGF transcription factors and intracellular 
proteolytic systems are involved in kidney cancer progression.
Keywords: renal cell carcinoma, metastasis, NF-кВ, HIF-1α, VEGF.
Introduction
Kidney cancer is among the cancers that have the 
highest growth rate and it is known as the most deadly 
urinary tract caner [1]. In the past years, there has been 
an increased understanding of the tumor biology of 
renal cell carcinoma (RCC) [2–4]. Hypoxia-inducible 
factor (HIF-1) is a heterodimeric transcription factor 
consisting of an alpha and beta subunits. Hydroxyla-
tion of proline and asparagine residues in HIF-1α re-
sults in their binding to the von Hippel-Lindau protein 
(pVHL), and is followed by HIF-1α polyubiquitination 
and degradation in the proteasome [5, 6]. The HIV 
activation results in vascular endothelial growth factor 
(VEGF) production [3].
NF-κΒ is the key transcription factor that controls 
the transcription of 150 target genes [7]. The process-
ing of p105 and p100 (NF-κΒ precursors) is mediated 
by the proteasome pathway [8]. The active form of 
the NF-κΒ transcription factor is p65/p50 heterodim-
ers [9–12]. It is known that NF-κΒ can regulate the 
HIF-1α level [13].
Proteolysis is one of the mechanisms for regulation 
of NF-κΒ and HIF-1α transcription factors, and the 
proteasome and calpain systems are the most possible 
factors to be involved. Proteasome is the multicatalytic 
complex that consists of the catalytic core (20S) with 
one or two regulatory particles attached to it [14]. Both 
the 20S and 26S proteasomes may be divided into two 
large groups of immune and constitutive forms that 
consist of either constitutive (β1β2β3β4β5β6β7) or im-
mune (LMP2, LMP7, MECL-1) subunits, respectively 
[15–19]. Calpains belong to the calcium-dependent 
proteases [20]. The calpain activity is implicated in 
several fundamental physiological processes, includ-
ing cytoskeletal remodelling, cellular signalling, 
apoptosis, and cell survival [21–25].
A decrease in HIF-1α degradation in the presence 
of proteasome inhibitors or under hypoxia leads to 
a significant increase in both VEGF and its mRNA 
expression in tumor cells [26, 27]. Moreover, calpains 
were shown to be involved in HIF-1α destruction [5]. 
Activation of NF-κΒ is effected by proteasomes. The 
key moment of NF-κΒ activation belongs to breaking 
the ties between the transcription factor and repressor 
protein known as I-κB [8, 11]. Currently, even greater 
significance is attached to the investigation on the 
participation of calpains in I-κB destruction [28]. The 
additional mechanism in NF-κΒ regulation serves the 
NF-κΒ protein forming from precursors, which are 
mediated by proteasomes through the modification 
of р105 protein [29].
Our preliminary data showed the role of proteolytic 
regulation in kidney cancer progression [18]. The aim 
of our study was to determine the proteasome and 
calpain activities in normal, primary and metastatic 
human RCC tissues and to reveal their association with 
VEGF, HIF-1α and NF-κΒ expression levels.
Material and Methods
A total of 93 patients with RCC were treated at 
the Cancer Research Institute of Tomsk National 
Research Medical Center, Russian Academy of Sci-
ences, Tomsk, Russian Federation (mean age 57.6 ± 
2.2 years). Localized RCC (T1-3N0M0) was revealed 
in 50 patients. Forty-three patients had metastatic 
RCC (T2-4N0-1M1). All patients with localized RCC 
underwent surgery (partial nephrectomy or simple 
nephrectomy). Diagnosis verification and cancer stage 
estimation for patients with metastatic RCC included 
the biopsy analysis. The combined modality treatment 
included pre-operative pazopanib targeted therapy 
administered at a dose of 800 mg every day for 2 
months. After completion of therapy, tumor response 
was evaluated according to the RECIST criteria, and 
radical nephrectomy was performed.
The study was approved by the Local Committee 
for Medical Ethics and all patients provided writ-
ten informed consent. Specimens were reviewed by 
two pathologists separately. Normal, malignant and 
metastatic tissue samples taken at a distance of not 
less than 2 cm from the tumor border were used. The 
frozen samples were stored at -80оС.
Preparation of tissue homogenates. Tissue samples 
(100 mg) were homogenized and then resuspended in 
300 μL of 50 mM Tris-HCl buffer (pH=7.5) contain-
ing 2 mM ATP, 5 mM MgCl2, 1 mM dithiothreitol, 1 
mM EDTA, and 100 mM NaCl. The homogenate was 
centrifuged at 10000×g for 60 minutes at 4°C.
Proteasome fractiation. All procedures were car-
ried out at 4°C. Proteins from tissue homogenates 
were fractionated with stepwise concentrations of 
ammonium sulfate [30]. The fractions were assayed 
for the proteasome activity.
Proteasome activity assay. Chymotrypsin-like ac-
tivity of the total proteasome, 26S and 20S pools was 
measured in cancer, metastatic and non-transformed 
tissue homogenates, and in the proteasome fractions, 
using the fluorogenic substrate N-Succinyl-Leu-Leu-
Val-Tyr-7-Amido-4-Methylcoumarin (Suc-LLVY-
AMC) in a Hitachi-850 (Japan) fluorimeter at an 
excitation wavelength of 380 nm and an emission of 
440 nm [31]. The 20S proteasome activity solution 
contained 20 mM Tris-HCl (pH=7.5), 1 mM dithio-
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threitol, and 30 μM Suc-LLVY-AMC. The 26S protea-
some activity solution additionally contained 5 mM 
MgCl
2 and 1 mM ATP. The reaction was carried out 
for 20 minutes at 37°C and then was stopped by the 
addition of 1 % sodium dodecyl sulfate. We used the 
proteasome inhibitor MG-132 to estimate the influence 
of other proteases. 
Calpains activity assay. The calpains activity was 
performed in tissue homogenates using the fluorogenic 
substrate N-Succinyl-Leu-Leu-Val-Tyr-7-Amido-4-
Methylcoumarin (Suc-LLVY-AMC) in a Hitachi-850 
(Japan) fluorimeter at an excitation wavelength of 380 
nm and an emission of 440 nm [32]. The calpains activ-
ity solution contained 100 мМ Tris-HCl (pH=7.3), 145 
мМ NaCl and 30 μM Suc-LLVY-AMC. Incubations 
were performed at room temperature for 30 minutes 
in absence or presence of 10 mМ CaCl
2
 and N-Acetyl-
L-leucyl-L-leucyl-L-norleucinal (calpain inhibitor I). 
Electrophoresis. SDS-PAGE was used, according 
to the method of Laemmli [33]. The samples were 
incubated for 5 to 10 min in 62.5 mM Tris-HCl buf-
fer (pH 6.8), containing 2.0 % (w/v) SDS, 5.0 % (v/v) 
mercaptoethanol, 10 % (v/v) glycerol, and 0.0012 % 
Bromophenol blue. 
Western Blot Analysis. After SDS-PAGE, the gels 
were allowed to equilibrate for 10 min in 25 mM 
Tris and 192 mM glycine in 20 % (v/v) methanol. 
The protein was transferred to 0.2-/xm pore-sized 
PVDF membrane (GE Healthcare, UK), either at 
150 mA or 100 V for 1 h by using a Bio-Rad Mini 
Trans-Blot electrophoresis cell according to the 
method described in the manual accompanying the 
unit. Before incubation with antibodies the PVDF 
membrane was incubated in 10 mM Tris-HC1 buf-
fer (pH 7.5), containing 150 mM NaC1 and 0.1 % 
(v/v) tween-20 for 2 hours. Then it was incubated in 
a 1:2500 dilution of monoclonal mouse anti-human 
α1α2α3α5α6α7, LMP7(Santa Cruz, USA), Rpt6 
(Enzo Life Science, USA) and of polyclonal rabbit 
anti-human LMP2, PA28β (Santa Cruz, USA) at 20 ºС 
for 1 h, followed by three consecutive washes in the 
10 mM Tris-HC1 buffer (pH 7.5), containing 150 mM 
NaCI. PVDF samples were incubated in Amersham 
ECL western blotting detection analysis system ac-
cording to the method described in the manual accom-
panying the unit and then were exposed to ECL-films 
(Amersham, USA). The results were standardized 
using the beta-actin expression in a sample and were 
expressed in percentages to the proteasome subunits 
content in non-transformed tissues. The expression of 
proteasome subunit in normal non-altered tissue was 
indicated as 100 %.
VEGF, HIF-1α and NF-κΒ (p65 and p50) determi-
nation. The pellets left after preparing tissue homoge-
nates were resuspended in 50 μL of 50 mM Tris-HCl 
buffer (pH=7.5) containing 2 mM ATP, 5 mM MgCl
2
, 
1 mM dithiothreitol, 1 mM EDTA, and 100 mM NaCl 
and then centrifugated at 14000×g for 10 minutes at 
4 °C. HIF-1α and NF-κΒ (p50 and p65) expression 
were measured with Caymanchem ELISA kits (USA) 
in Anthos 2020 ELISA-microplate reader (Biochrom, 
UK). Nuclear extracts were prepared and purified ac-
cording to manufacturer’s instructions. 
Statistical analysis. Statistical analysis was per-
formed using SPSS 19.0 software. Data were ex-
pressed as median (interquartile ranges). To evaluate 
the difference, either the Student t test or the Mann-
Whitney test was applied. Correlation analysis on data 
was carried out with Spearman Rank Correlation test. 
Kruskal-Wallis ANOVA and median Test were used for 
comparing two or more independent groups.
Results
High expression levels of NF-κΒ, HIF-1α and VEGF 
were found in RCC tissues. The NF-κΒp50 expression 
was 1.5 times higher in cancer tissues than in normal 
tissues (Table 1). Our results estimated the prevalence 
of active forms of NF-κΒ transcription factor in tumors. 
The NF-κΒр65 and NF-κΒp50 expression levels were 
5.5 (2.8-8.7) and 6.3 (3.3‑10.0) RLU per mg protein 
in a well, respectively. The NF-κB p65 to NF-κΒp50 
ratio of less than 1.0 is known to be a sign of nonactive 
dimmers of NF-kB [12]. The NF-κΒ р65/р50 ratio of 
1.1 in cancer tissues indicated NF-κΒ activation. In 
cancer tissues, the HIF-1α and VEGF expression levels 
were 4.2 and 12.45 times higher than those observed 
in non-transformed tissues (4.2 (2.2‑7.9)) RLU per 
mg protein and 128.0 (81.8‑168.2) pg /per mg protein, 
respectively). Thus, the high levels of transcription and 
growth factors were revealed in RCC tissues.
Proteasome and calpain activities were decreased 
in kidney cancer tissues. The total proteasome and 26S 
and 20S proteasome activities were found to be lower 
in RCC tissues than in non-transformed tissues. The 
proteasome activity is known to be associated with the 
content of proteasome subunits [16, 34]. The expres-
sion of the proteasome subunits α1α2α3α5α6α7 was 
higher in cancer tissues than in non-transformed tissues 
(agreed standard) (p<0.05). However, the expression 
levels of LMP2 immune proteasome subunit and 
РА28β proteasome activator subunit were decreased 
in cancer tissues. The difference in their levels be-
tween cancer tissues and normal surrounding tissues 
was 30% (Figure 1). The decreased 20S proteasome 
activity was likely dependent on a low level of PA28β 
subunit of the proteolytic complexes. A nonparametric 
correlation was revealed between the LMP2 level and 
proteasome activity (r=0.26; p=0.04). Proteasome 
activity depression was accompanied by a low calpain 
activity. The calpain activity was 1.4 times lower in 
RCC tissues than in normal tissues. It should be noted 
that proteasomes and calpains play a significant role in 
cancer development, tumor progression and metastatic 
spread due to their impact on transcription and growth 
factor levels. Thus, changes in the protease activity in 
kidney cancer tissues could be followed by the altered 
expression of transcription and growth factors. 
Development of metastasis leads to changes in 
the protease activity and expression of transcription 
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and growth factors in primary cancer tissues. Kidney 
cancer progression and metastasis are followed by 
significant changes in proteolysis. Table 2 shows the 
activity of proteasomes and calpains in metastatic and 
non-metastatic tissues. Patients with Т2-4N0-1M1 
(metastatic cancer) had a 1.3-fold decrease in the to-
tal proteasome activity and a 1.3-fold increase in the 
calpain activity compared to Т1-3N0-1M0 patients 
(non-metastatic tumors). Calpains are known to be 
responsible for limited protein proteolysis in cells. In 
the absence of proteasomes, they could damage and 
modify proteins and peptides [19]. I-κB, the endog-
enous inhibitor of NF-κΒ and HIF-1α transcription 
factors, is a substrate of proteases, and its incomplete 
proteolysis could lead to the accumulation of angio-
genic factors in cancer cells and metastasis develop-
ment [5, 19].
The development of metastatic spread was found 
to be accompanied by increased levels of transcription 
factors and VEGF expression (Table 3). The produc-
tion of NF-κΒp65 was 3.2 times higher in tumor 
tissues than in normal non-transformed tissues. So, 
this fact was accompanied by a 5.0-fold increase in 
the NF-κΒp65 to NF-κΒp50 ratio. The HIF-1α and 
VEGF expression levels were respectively 9- and 2.8 
times higher in metastatic RCC tissues than in non-
metastatic tissues.Thus, the progressive depression of 
protease activity in RCC tissues was associated with 
high expression levels of transcription factors and 
VEGF. Their accumulation in tumors led to cancer 
progression and metastasis.
Changes in NF-κΒ, HIF-1α and VEGF expres-
sion levels in primary cancer and metastatic tissues. 
NF-κΒp50 expression in metastatic and primary RCC 
tissues was higher than in normal non-transformed tis-
sues. The NF-κΒp65 level was low both in metastatic 
and normal kidney parenchyma. And this molecular 
factor is reduced in 2.0 fold in comparison to RCC 
tissue. Interestingly, the HIF-1α content was 1.7 times 
higher in metastatic than in normal tissues. The VEGF 
expression was higher in metastatic and primary RCC 
tissues than in normal kidney tissues. We used the 
Kruskal Wallis (nonparametric ANOVA) Test and 
Median Test to analyze variances of multiple groups. 
We found significant differences in HIF-1 (p=0.0001; 
p=0.0001), NF-kBp50 (p=0.0002; p=0.0004), NF-
kBp65 (p=0.02; p=0.01) and VEGF (p=0.0002; 
p=0.004) expression levels between normal, primary 
and metastatic RCC tissues.
Proteasome and calpain activities in primary and 
metastatic RCC tissues. Figure 2 shows the protease 
activity in distant metastatic tissues. Proteasome activ-
ity was 2.2 times lower in metastatic RCC tissues than 
in normal kidney tissues and was 1.5 times lower in 
metastatic than in primary RCC tissues. No difference 
in calpain activity was found between metastatic tis-
Figure 2. Total proteasome activity, 26S and 20S proteasome 
activity and calpain activity in kidney cancers. The results repre-
sent the Me (Q1-Q3); * in comparison with normal tissue, p<0.05. 
** in comparison with cancer tissues. proteasome depression is 
accompanied with fall of calpains activity. It is detected the growth 
in total proteasome and calpain activity in metastasis tissues 
compared to primary cancer tissues
Figure 1. proteasome subunit content in RCC.
A - Western Blotting analysis shows the expression of proteasome subunits in cancer and non-transformed tissues: 
2, 3 – Western Blots of cancer tissues; 1, 4 - Western Blots of non-transformed tissues. 
B – The expression of proteasome subunit in normal non-altered tissue is indicated as 100%.
* - in comparison with normal tissue, p<0.05; the results are standardized using the β-actin expression in a sample and are expressed in 
percentages to the proteasome subunits content in non-transformed tissues
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Table 1
NF-κΒp65, NF-κΒp50, HIF-1α and VEGF expressions in normal and kidney cancer tissues
Samples
NF-κΒp65 expression, 
RLU /per mg of protein 
in well
NF-κΒp50 expression, 
RLU /per mg of protein 
in well
HIF-1α expression, RLU 
/per mg of protein in 
well
VEGF expression, pg/
mg of protein
Non-transformed normal 
tissue, n=16
4,88 (4,66–5,21) 4,16 (3,76–4,66) 0,98 (0,62–1,18) 10,28 (8,46–14,3)
Kidney cancer tissue, 
n=69
7,0 (4,7–15,4)* 7,0 (4,7–14,7)* 4,88 (2,56–8,6)* 69,3 (27,5–139,75)*
Note: the results represent the Me (Q1-Q3); * in comparison with normal tissue, p<0,05.
Table 2
Total proteasome activity, 26S and 20S proteasome activities and calpain activity in metastatic and non-
metastatic RCC
Samples
Proteasome activity, ⋅103 Unit/per mg of protein Calpains activity, ⋅103 
Unit/per mg of proteinTotal proteasome activity 26S proteasome activity 20S proteasome activity
Non-metastatic RCC 
tissue, n=63
36.1 (20.0–102.0) 12.5 (7.3–21.3) 28.0 (16.7–65.7) 33.5 (16.8–33.5)
Metastatic RCC 
tissue, n=30
27.0 (5.5–43.1)* 10.2 (3.3–23.3) 30.1 (20.0–49.4) 44.7 (18.6–54.3)*
Note: the results represent Me (Q1-Q3); * – in comparison to non-metastatic RCC, p<0,05.
Table 3
NF-κΒp65, NF-κΒp50, HIF-1α and VEGF expressions in metastatic and non-metastatic RCC
Samples
NF-κΒp65 
expression, RLU /
per mg of protein 
in well
NF-κΒp50 
expression, RLU /
per mg of protein 
in well
Coefficient 
NF-κΒp65/ p50
HIF-1α expression, 
RLU /per mg of 
protein in well
VEGF expression, 
pg/mg of protein
Non-metastatic 
RCC, n=45
5.0 (2.0–7.9) 6.4 (3.3–10.0) 0.6 (0.3–2.0) 4.2 (2.2–7.8) 71.5 (38.3–139.7)
Metastatic RCC, 
n=30
11.3 (6.8–15.7)* 6.2 (4.4–9.7) 3.0 (1.6–3.0)* 7.9 (6.2–8.5)* 205.4 (131.7–261.5)*
Note: the results represent the Me (Q1– Q3); * in comparison with non-metastatic RCC tissue, p<0,05.
sues and normal kidney tissues. However, the calpain 
activity was 1.75 times higher in metastatic RCC tis-
sues than in primary kidney cancer tissues. The results 
of non-parametric ANOVA analysis (Kruskal-Wallis 
test and Median test) showed significant changes in 
the total proteasome (p=0.0001; p=0.0001) and calpain 
(p=0.03; p=0.06) activities in primary non-metastatic 
and metastatic tissues. Despite the fact that the contri-
bution of the cellular protease system to tumorigenesis 
remains unclear, we decided to evaluate the NF-κΒ, 
HIF-1α and VEGF expression levels in primary and 
metastatic kidney cancer tissues. The recent study have 
documented that the increase of proteasome and cal-
pains activity is required for sufficient carcinogenesis 
[20]. Thus, the protease activation in metastatic tissues 
is accompanied with increased NF-κΒp50, HIF-1α and 
VEGF expression levels. Metastatic cancer cells are 
known to have the altered biological features. In our 
study we found the correlation between the aggressive 
behavior of cancer cells and proteolysis activity. 
Correlations between the proteasome activity, 
transcription factors and VEGF expression were found 
in RCC tissues. To further examine the potential 
importance of proteases in RCC metastasis develop-
ment, we analyzed the correlations between them 
and transcription and growth factor levels. Positive 
relationships between the activities of all proteasome 
pools in tumors were found. We observed statistically 
significant correlations between the 20S and 26S pro-
teasome activities (r=0.60; p<0.05), total proteasome 
and 20S activities (r=0.80; p<0.05), and between the 
total and 26S proteasome activities (r=0.78; p<0.05). 
A positive correlation was found between the total pro-
teasome activity, 26S proteasome activity and calpain 
activity (r1=0.56, p=0.00001; r2=0.57, p=0.00002; 
r3=0.63, p=0.00001, respectively). Goldberg A.L. [8] 
reported that the HIF-1α expression level was influ-
enced by NF-kB transcription factors. The analysis of 
our data showed the relationships between NF-κB р65 
and HIF-1α expression levels (r=0.9; p=0.0001) and 
between VEGF and HIF-1α expression levels (r=0.8; 
p=0.001). The effect of NF-κΒ on angiogenic growth 
factor was likely to be mediated through HIF-1 expres-
sion changes. The association between HIF-1α and 
VEGF expression was also detected in cancer tissues 
(r=0.97; p=0.0001).
Discussion
The proteolytic regulation of transcription and 
growth factors is of great importance in kidney cancer 
progression. In RCC, HIF-1α level was associated 
with low 26S proteasome activity (r= -0.36; p=0.04). 
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The loss of von Hippel-Lindau gene was followed by 
HIF-1α overexpression through blockage of its protea-
some degradation [26, 27]. The intensive angiogenesis 
is the result of this process. The NF-κΒр50 level was 
correlated with 20S proteasome activity. The post-
translational modification of p105 was performed 
by proteasome [28]. The nonparametric nonlinear 
regression analysis was carried out to study the im-
pact of proteases on transcription factor expression. It 
was found that the induced 20S proteasome activity 
(Beta=0.93; p<0.05) and depressed 26S proteasome 
activity (Beta=–0.58; p<0.05) led to the increased 
NF-κΒp50 level in cancer cells.
There are miltiple crosstalks between the expres-
sion of transcription and growth factors in RCC. 
Proteolysis is considered the most significant. The 
26S proteasome plays the main role in HIF-1α degra-
dation, and 20S proteasome participates in NF-κΒp50 
production.
Low proteasome and calpain activities are specific 
to RCC. The increase in the protease activity is fol-
lowed by RCC metastasis development. The block-
age of HIF-1α degradation and the increased level 
of VEGF result in non-effective proteolysis. In RCC 
culture, P. van Uden [13] revealed the influence of 
NF-κΒ on HIF-1α transcription. Our findings highlight 
the potential contribution of intracellular proteases to 
kidney cancer metastasis. The increased NF-κΒp65 
expression is likely can influence on HIF-1 produc-
tion in metastatic RCC and can be the main factor of 
cancer progression. There are reports on the associa-
tion between the NF-κB activity and VEGF m RNA 
expression in breast cancer cells [35]. Our results are 
consistent with other recent studies, which indicate that 
the VEGF level is positively correlated with NF-κB 
р65 expression in cancer tissues.
Conclusion
Our results showed the relationship between the 
proteasome/calpain activity and transcription factor 
expression in primary and metastatic RCC. The hypo-
thetic schema of proteolytic regulation of transcription 
factors and VEGF expression in RCC was obtained. 
The depression of cellular proteolytic systems and 
increase in the levels of transcription and growth fac-
tors were found in primary cancer tissues, resulting 
in metastasis development. High levels of NF-κΒ, 
HIF-1α and VEGF were found in primary metastatic 
tumors. A significant difference in cancer cells was 
found between primary and metastatic tissues. In dis-
tant metastatic tissues, proteolysis activation was ac-
companied by high levels of transcription and growth 
factors. The altered biological features were shown in 
metastatic tissues. The increased protease activity in 
metastatic tissues was followed by high NF-κΒp50, 
HIF-1α and VEGF levels. Thus, proteasomes and 
calpains play a significant role in metastasis develop-
ment. A decreased protease activity is necessary for the 
aggressive behavior of cancer cells and kidney cancer 
dissemination. Induced proteolysis in metastatic tis-
sues is required for RCC progression.
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